education
Download App
FAQs
Thailand
search
Sign In
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Country
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
search
UserName
Profession
Email
Account
Manage Account
Change Password
Sign Out
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Other Services
Education
Download App
Country
Thailand
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
Support
FAQs
Account
Sign In
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Advertisement
Advertisement
>
Drugs
>
Opalmon
>
...
Drugs
>
Opalmon
Opalmon
Opalmon
Manufacturer:
Ono Pharmaceutical
Distributor:
Zuellig Pharma
Marketer:
Meiji
SELECT
Concise Prescribing Info
Full Prescribing Info
Contents
Description
Action
Indications/Uses
Dosage/Direction for Use
Overdosage
Contraindications
Special Precautions
Use In Pregnancy & Lactation
Adverse Reactions
Drug Interactions
Caution For Usage
Storage
MIMS Class
ATC Classification
Thai FDA Category
Presentation/Packing
Concise Prescribing Info
Full Prescribing Info
Contents
Description
Action
Indications/Uses
Dosage/Direction for Use
Overdosage
Contraindications
Special Precautions
Use In Pregnancy & Lactation
Adverse Reactions
Drug Interactions
Caution For Usage
Storage
MIMS Class
ATC Classification
Thai FDA Category
Presentation/Packing
Concise Prescribing Info
Contents
Limaprost alfadex
Indications/Uses
Improvement of various ischemic symptoms eg, ulcer, pain & feeling of coldness associated w/ thromboangiitis obliterans. Improvement of subjective symptoms (pain & numbness of lower legs) & gait ability associated w/ acquired lumbar spinal canal stenosis (in patients w/ bilateral intermittent claudication showing normal SLR test result).
Click to view Opalmon detailed prescribing information
Dosage/Direction for Use
Adult
Improvement of various ischemic symptoms eg, ulcer, pain & feeling of coldness associated w/ thromboangiitis obliterans
30 mcg daily in 3 divided doses.
Improvement of subjective symptoms (pain & numbness of lower legs) & gait ability associated w/ acquired lumbar spinal canal stenosis (in patients w/ bilateral intermittent claudication showing normal SLR test result)
15 mcg daily in 3 divided doses.
Click to view Opalmon detailed prescribing information
Overdosage
View
Opalmon overdosage
for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Pregnancy.
Click to view Opalmon detailed prescribing information
Special Precautions
Patients w/ bleeding tendency or under treatment w/ antiplatelets, thrombolytics or anticoagulants; severe lumbar spinal canal stenosis.
Click to view Opalmon detailed prescribing information
Use In Pregnancy & Lactation
Click to view Opalmon detailed prescribing information
Adverse Reactions
Stomach discomfort, rash, headache, diarrhea.
Click to view Opalmon detailed prescribing information
Drug Interactions
May accelerate bleeding tendency w/ antiplatelets eg, aspirin, ticlopidine, cilostazol, thrombolytics eg, urokinase, anticoagulants eg, heparin, warfarin.
Click to view Opalmon detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine...
Click to view Opalmon detailed prescribing information
Storage
View
Opalmon storage
conditions for details to ensure optimal shelf-life.
Description
View
Opalmon description
for details of the chemical structure and excipients (inactive components).
Action
View
Opalmon mechanism of action
for pharmacodynamics and pharmacokinetics details.
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AC28 - limaprost ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Thai FDA Category
D
Presentation/Packing
Form
Opalmon tab 5 mcg
Packing/Price
210's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Sign up for Free to Continue Reading
Continue with Google
Sign Up With Email
Already a member?
Sign In
Sign up for Free to Continue Reading
Continue with Google
Sign Up With Email
Already a member?
Sign In